Lipidtherapie bei kardiometabolischen Patienten: Lipidzielerreichung – schnell und effektiv

Cardiovascular death is the most common cause of death in western countries. Therefore, the European Society of Cardiology (ESC) and the European Society of Atherosclerosis (EAS) have developed a joint consensus paper targeting the reduction of cardiovascular events and death.

ing, it is of utmost importance to pay attention to individually targeted lipid-lowering therapy, which requires different low density lipoprotein cholesterol (LDL-C) targets, depending on the treatment goal. Since the ESC guidelines from 2019 it is recommend to achieve an LDL-C target of at least <55 mg/ dL after a cardiovascular event or in cases of very high cardiovascular risk. Thus, several potent pharmacological therapies are available which should be administered in a stepwise approach, including statins, ezetimibe, proprotein convertase subtilisin/ kexin type 9 (PCSK9) inhibitors and inclisiran, which is a small interfering RNA therapy that inhibits the synthesis of PCSK9.